Explore 3 Stock Ideas & Industry Insights Download Free Report

CONMED Corporation

Healthcare US CNMD

33.08USD
-0.77(2.27%)

Last update at 2026-06-03T20:10:00Z

Day Range

32.1334.19
LowHigh

52 Week Range

33.2160.63
LowHigh

Fundamentals

  • Previous Close 33.85
  • Market Cap1182.47M
  • Volume733865
  • P/E Ratio26.27
  • Dividend Yield1.51%
  • EBITDA201.65M
  • Revenue TTM1374.72M
  • Revenue Per Share TTM44.29
  • Gross Profit TTM 740.57M
  • Diluted EPS TTM1.46

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 71.12M 163.03M 80.83M -70.86200M 73.11M
Minority interest - - - - -
Net income 47.05M 132.42M 64.46M -80.58200M 62.54M
Selling general administrative 591.97M 453.99M 505.82M 454.04M 414.75M
Selling and marketing expenses - 65.34M - - -
Gross profit 750.48M 733.03M 676.25M 571.25M 568.04M
Reconciled depreciation 74.28M 71.86M 71.61M 69.52M 70.74M
Ebit 102.20M 200.33M 120.60M 70.05M 37.85M
Ebitda 176.49M 272.18M 192.48M -41.95700M 108.59M
Depreciation and amortization 74.28M 71.86M 71.87M -112.01100M 70.74M
Non operating income net other - - - -112.01100M -1.12700M
Operating income 102.62M 200.33M 120.60M 70.05M 37.85M
Other operating expenses 1272.10M 1106.69M 1124.14M 975.42M 900.92M
Interest expense 31.09M 37.30M 39.77M 28.91M 35.48M
Tax provision 24.06M 30.61M -28.36500M 9.72M 10.56M
Interest income - - - - -
Net interest income -31.08700M -37.29700M -39.71400M -28.90500M -35.48500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 24.06M 30.61M 16.37M 9.72M 10.56M
Total revenue 1374.72M 1307.02M 1244.74M 1045.47M 1010.63M
Total operating expenses 647.85M 532.71M 555.64M 501.19M 458.32M
Cost of revenue 624.25M 573.98M 568.50M 474.23M 442.60M
Total other income expense net -31.50500M -37.29700M -39.77500M -140.91600M 35.26M
Discontinued operations - - - - -
Net income from continuing ops 47.05M 132.42M 57.97M -80.58200M 62.54M
Net income applicable to common shares - - - -80.58200M 62.54M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2325.75M 2306.25M 2300.02M 2297.59M 1766.02M
Intangible assets 582.05M 617.66M 649.48M 681.80M 471.05M
Earning assets - - - - -
Other current assets 28.67M 31.10M 30.75M 28.62M 23.75M
Total liab 1292.65M 1343.57M 1465.80M 1552.05M 980.58M
Total stockholder equity 1033.10M 962.68M 834.22M 745.54M 785.43M
Deferred long term liab - - - 66.72M 68.54M
Other current liab 220.68M 175.17M 214.29M 143.76M 65.71M
Common stock 0.31M 0.31M 0.31M 0.31M 0.31M
Capital stock 0.31M 0.31M 0.31M 0.31M 0.31M
Retained earnings 588.77M 560.28M 452.53M 412.63M 496.61M
Other liab - - - 258.66M 98.80M
Good will 807.01M 805.36M 806.84M 815.43M 617.53M
Other assets - - - 85.82M 89.03M
Cash 40.82M 24.46M 24.30M 28.94M 20.85M
Cash and equivalents - - - - -
Total current liabilities 315.04M 278.13M 310.73M 296.55M 196.65M
Current deferred revenue - - -8.21700M 9.65M 60.49M
Net debt 794.12M 881.32M 966.96M 1025.88M 663.81M
Short term debt 0.71M 0.71M 8.22M 69.75M 12.25M
Short long term debt 0.71M 0.71M 0.71M 69.75M 12.25M
Short long term debt total 834.94M 905.78M 991.25M 1054.82M 684.66M
Other stockholder equity 490.31M 460.95M 431.55M 390.46M 342.72M
Property plant equipment - - - 115.61M 108.86M
Total current assets 672.86M 640.01M 615.65M 581.23M 460.12M
Long term investments - - - - -
Net tangible assets - - - -751.68300M -340.82900M
Short term investments - - - - -
Net receivables 247.83M 237.73M 242.28M 191.34M 183.88M
Long term debt 834.23M 905.07M 973.14M 985.08M 672.41M
Inventory 355.54M 346.72M 318.32M 332.32M 231.64M
Accounts payable 93.65M 102.25M 88.22M 73.39M 58.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -46.29500M -58.85700M -50.17000M -57.85800M -54.20300M
Additional paid in capital - - - - -
Common stock total equity - - - 0.31M 0.31M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 412.63M 496.61M
Treasury stock - - - -22.77600M -54.05100M
Accumulated amortization - - - - -
Non currrent assets other 137.19M 116.36M 96.11M 93.88M 98.80M
Deferred long term asset charges - - - - -
Non current assets total 1652.89M 1666.24M 1684.37M 1716.37M 1305.89M
Capital lease obligations - - - - -
Long term debt total - - - 985.08M 672.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -13.08400M -21.49500M -249.52900M -14.86600M
Change to liabilities - - - 10.80M 15.27M
Total cashflows from investing activities -20.95600M -13.08400M - -249.52900M -14.86600M
Net borrowings -74.58700M -72.00000M - 340.19M -83.24300M
Total cash from financing activities -135.82000M -151.00000M -110.43200M 225.00M -101.54800M
Change to operating activities - - - -26.95900M -11.94700M
Net income 47.05M 132.42M 64.46M -80.58200M 62.54M
Change in cash 16.36M 0.16M -4.64600M 8.10M -6.50900M
Begin period cash flow 24.46M 24.30M 28.94M 20.85M 27.36M
End period cash flow 40.82M 24.46M 24.30M 28.94M 20.85M
Total cash from operating activities 170.69M 166.97M 125.35M 33.37M 111.77M
Issuance of capital stock - - - - -
Depreciation 74.28M 51.30M 51.40M 69.52M 70.74M
Other cashflows from investing activities -1.15000M - - -227.74400M -
Dividends paid 24.75M 24.65M 24.50M 23.96M 23.26M
Change to inventory -6.73300M -31.63300M 14.07M -78.56400M -37.80600M
Change to account receivables -2.36100M -1.61900M -47.06800M -5.20300M -9.15900M
Sale purchase of stock - - - 2.47M -
Other cashflows from financing activities -36.48700M -54.34900M 2.07M 1146.94M 382.12M
Change to netincome - - - 130.22M 20.24M
Capital expenditures 19.81M 13.08M 19.03M 21.79M 14.87M
Change receivables - - - -5.20300M -9.15900M
Cash flows other operating - - - -17.73500M -24.00500M
Exchange rate changes - - - - -1.86500M
Cash and cash equivalents changes - - - 8.84M -6.50900M
Change in working capital -11.45300M -39.72400M -39.57900M -90.69800M -55.69700M
Stock based compensation 28.32M 25.56M 24.26M 21.73M 16.34M
Other non cash items 28.96M -14.79600M 24.11M 119.44M 14.84M
Free cash flow 150.88M 153.88M 106.32M 11.58M 96.90M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CNMD
CONMED Corporation
-0.77 2.27% 33.08 26.27 27.17 0.86 1.16 1.45 11.28
ABT
Abbott Laboratories
0.02 0.02% 86.99 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation
1.70 0.58% 295.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
4.20 5.69% 77.95 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
0.01 0.02% 47.69 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

CONMED Corporation

11311 Concept Boulevard, Largo, FL, United States, 33773

Key Executives

Name Title Year Born
Mr. Curt R. Hartman Chairman, CEO & Pres 1964
Mr. Todd W. Garner Exec. VP & CFO 1969
Mr. Patrick J. Beyer Pres of International & Global Orthopedics 1966
Mr. Stanley W. Peters III Pres of Advanced Surgical & Advanced Endoscopic Technologies 1975
Mr. Daniel S. Jonas Esq. Special Counsel & Corp. Sec. 1964
Ms. Heather L. Cohen Exec. VP and Chief HR & Legal Officer 1973
Mr. Peter K. Shagory Exec. VP of Strategy & Corp. Devel. 1969
Mr. John E. Kennedy Special Advisor 1958
Ms. Shanna L. Cotti-Osmanski Exec. VP of Information Technology & CIO 1977
Mr. David R. Murray Pres of ConMed Electrosurgery 1948

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.